MadecassosidevsResveratrol

Madecassoside (triterpene glycoside from Centella asiatica) inhibits NF-kappa B nuclear translocation by preventing I-kappa B alpha degradation, suppressing transcription of pro-inflammatory cytokines (TNF-alpha, IL-1beta, IL-6) and COX-2. Activates Nrf2, upregulating antioxidant enzymes (heme oxygenase-1, NQO1, glutathione peroxidase). Stimulates collagen type I synthesis through TGF-beta/Smad3 signaling in fibroblasts, upregulating COL1A1. Promotes keratinocyte migration (wound closure) by enhancing integrin expression and matrix metalloproteinase activity. Inhibits hyaluronidase, preserving skin hyaluronic acid. Reduces VEGF expression, inhibits MMP-1. Comprehensive: anti-inflammatory, antioxidant, pro-collagen, wound-healing. Used in pharmaceutical wound care (Madecassol) and K-beauty. Ideal for post-procedure recovery, retinoid irritation, sensitive skin.

Resveratrol activates SIRT1 (sirtuin 1), a NAD+-dependent deacetylase that deacetylates histones and non-histone targets including p53, FOXO transcription factors, and NF-κB, regulating cellular stress response, DNA repair, autophagy, and inflammatory pathways in keratinocytes and fibroblasts. It scavenges superoxide anion, hydroxyl radical, and metal-induced free radicals through its phenolic hydroxyl groups. Resveratrol inhibits NF-κB nuclear translocation and downstream cytokine production (TNF-α, IL-1β, IL-6), reducing UV-induced inflammation. It inhibits tyrosinase (mild brightening), matrix metalloproteinase-9 (MMP-9, gelatinase B) to prevent collagen and elastin breakdown, and AP-1 (c-Fos/c-Jun) to reduce photoaging-related gene expression. It may also activate Nrf2, upregulating antioxidant enzymes (HO-1, NQO1). Topical application achieves higher skin tissue concentrations than oral supplementation due to first-pass metabolism. Stability is improved in anhydrous or encapsulated formulations.